An investigative stem cell-based therapy called PEC-Direct, designed to act as a replacement pancreas, has the potential to provide blood sugar control in patients with high-risk type 1 diabetes, suggests a clinical study presented Saturday, June 11 at ENDO 2022, the Endocrine Society’s annual meeting in Atlanta, Ga.
— Read on www.endocrine.org/news-and-advocacy/news-room/2022/stem-cell-based-therapy-shows-promise-in-treating-high-risk-type-1-diabetes
BOOM! MAKE THEM STRIDES & SAVE THEM LIFES! ESPECIALLY MY BOY CJ! #thankyou #hopeful!
Type 1 diabetic Warrior 